To evaluate the diagnostic efficacy of 68Ga FAPI PET/CT in myelofibrosis and to identify fibrosis grades.
To evaluate the diagnostic efficacy of 68Ga FAPIPET/CT imaging in patients with myelofibrosis, compared with conventional CT.
Age ≥18 years old;
Cohort 1: Patients with suspected or confirmed myelofibrosis; Cohort 2: Patients with primary/secondary myelofibrosis who were not treated with ruxolitinib.
The expected survival time is over 3 months
Voluntarily sign informed consent.
Known allergic history to 68Ga FAPI or its excipients;
Patients who can not tolerate intravenous drug administration (such as needle fainting and blood fainting history);
Those who are not suitable for or unable to complete imaging tests such as PET due to special reasons, including claustrophobia and radiophobia;
pregnant and lactating women;
Chinese people
Cohort
Prospective
68Ga FAPI PET/CT
Diagnostic test68Ga FAPI PET/CT
Sensitivity
Sensitivity of 68Ga-FAPI PET/CT Imaging for the detection of Myelofibrosis.
Specificity
Specificity of 68Ga-FAPI PET/CT Imaging for the detection of Myelofibrosis.
Positive prediction rate
Positive prediction rate of 68Ga-FAPI PET/CT Imaging for the detection of Myelofibrosis.
Negative prediction rate
Negative prediction rate of 68Ga-FAPI PET/CT Imaging for the detection of Myelofibrosis.
Click on the lead sponsor to view all of their trials.
